Dyne Therapeutics reporta EPS GAAP de -$1,08, abaixo das estimativas por $0,33 (NASDAQ:DYN)
· seekingalpha.com
Comunicado de imprensa da Dyne Therapeutics (DYN): EPS GAAP do 2º trimestre de -$1,08 decepciona por $0,33.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...